

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44444 A2

(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/JP00/08873

(22) International Filing Date: 14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 9929542.0 14 December 1999 (14.12.1999) GB

(71) Applicant (for all designated States except US): GLAXO WELLCOME KABUSHIKI KAISHA [JP/JP]; Shinjuku Maynds Tower, 1-1, Yoyogi 2-chome, Shibuya-ku, Tokyo 151-8566 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HASHIMOTO, Yasuhiro [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). TAKEMOTO, Yoshihiro [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). FURUTA, Masaaki [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). SAKAI, Yutaka [JP/JP]; Tsukuba Research Laboratories, Glaxo Wellcome Kabushiki Kaisha, 43, Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP).

(74) Agents: SUZUYE, Takehiko et al.; Suzuye & Suzuye, 7-2, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-0013 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/44444 A2

(54) Title: IKK4

(57) Abstract: A novel inhibitory kappa B kinase (IKK) is disclosed herein as IKK4. Polynucleotides encoding IKK4, expression vectors comprising said polynucleotides and screening methods for identifying therapeutic modulators of IKK4 activity are also disclosed.

1

D E S C R I P T I O N
IKK4

5 This invention relates to a novel IKK kinase protein, IKK4, nucleotides encoding for it, vectors and host cells containing the same and methods for screening for modulators of said IKK4 protein for treatment of conditions involving inflammation.

10 The transcription factor NF- κ B controls the activation of various genes in response to pathogens and pro-inflammatory cytokines. Thus, for example, NF- κ B is activated by various kinds of stimulation including tumour necrosis factor alfa (TNF alfa) and interleukin -1 (IL-1), bacterial LPS, viral infection, antigen receptor cross-linking of T and B cells, calcium ionophores, phorbol esters, UV radiation and free radicals (for reviews, see Varma et al., 1995, Genes Dev., 9, 2723-2735; Baueuerle and Baltimore, 1996, Cell, 87, 13-20), (see Figure 1).
15 NF- κ B in turn controls the activation of various genes in response to these stimuli. Activation of these various genes in turn may result in the production of cytokines, chemokines, leukocyte adhesion molecules, hematopoietic growth factors and may also effect development and cell death as well as cell survival (see Figure 1). Specifically, the transcription factor NF- κ B controls the activation
20 of various genes in response to pathogens and pro-inflammatory cytokines. The NF- κ B activity is regulated through interaction with specific inhibitors, I κ Bs. Upon cell stimulation, the I κ Bs are rapidly phosphorylated and then undergo ubiquitin-mediated proteolysis, resulting in the release of active NF- κ B (Baldwin, 1996, Annu. Rev. Immunol., 14, 649-681; Baueuerle and Baltimore, 1996, Cell, 87, 13-20), (see Figure 2). It has been reported that the 700 kDa complex
25 specifically phosphorylated I κ B α at S32 and S36 (Chen et al., 1996, Cell, 84, 853-862).

30 Several groups found that two kinases termed IKK1 (IKK α) and IKK2 (IKK β), were the subunits of the kinase complex. These groups showed that the IKK immunoprecipitates, derived from the TNF α or IL-1 stimulated cells which are able to phosphorylate I κ B in vitro. In addition to these observations, two groups reported that IKK1 and IKK2 purified from insect cells were able to phosphorylate I κ B in vitro. These results suggested that IKK directly phosphorylates I κ Bs. The over expression of anti-sense IKK1, kinase-inactive
35

IKK1 or IKK2 resulted in the inhibition of NF- κ B activation mediated by TNF α and IL-1. These results suggest that IKKs are critical kinases in the NF- κ B activation pathway (May and Ghosh, 1998, Immunol. Today 19, 80-88; Stancovski and Baltimore, 1997, Cell, 91, 299-302). It has, however, not been understood how upstream signals are transmitted to the kinase complex, or whether different kinase complexes might exist to phosphorylate distinct I κ Bs.

NEMO (NF- κ B essential modifier) and IKK γ (human homologue of the mouse NEMO) were isolated from purified IKK complex, and the inhibition of NEMO/IKK γ gene expression impaired the cytokine induced NF- κ B activation via IKK1 and IKK2. In NEMO deficient cells, smaller complexes of Mr 3,000-4,000 are formed, though the normal complex is Mr 7,000-9,000, suggesting that NEMO/IKK γ physically link I κ B kinase to upstream activators (Scheidereit, Nature, 1998, 395, 225-226).

The IKK-complex-associated protein (IKAP) was isolated from the IKK complexes. IKAP binds to I κ B kinases and NIK and the complex, containing three kinases, leads to the maximum phosphorylation of I κ B as compared to the complex containing one or two kinases. Accordingly, IKAP may act as scaffold proteins that link NIK or other molecules to IKK1 and IKK2 (Scheidereit, Nature, 1998, 395, 225-226). Accumulating evidence suggests that the IKK complex consists of several essential molecules, however, the molecular mechanisms that control the signalling complex were not well understood. Therefore, further association molecules were needed to complete the picture.

KIAA0151 was originally isolated from the KG-1 cDNA library (Nagase et al., 1995, DNA Res, 2, 167-174). KIAA0151 was identified as a potential Ser/Thr kinase, however, the importance of the molecule was not recognised. We have now found that KIAA0151 is similar to IKK1 and IKK2 using a computer homology analysis. KIAA0151, renamed IKK3, has a 21% homology with IKK1 and 23% with IKK2. IKK3 was able to phosphorylate I κ B family proteins and directly phosphorylate I κ B in vitro. The over expression of IKK3 leads to the activation of various inflammatory genes, such as IL-8, IL-6 and RANTES. These genes contain the NF- κ B site in the gene regulation region. We know that IKK3 has an effect on IL-8 expression in HeLa cells and also that IKK3 phosphorylates

NF- κ B. Moreover, it is known that the NF- κ B site has an important role in IL-8 regulation. Our results suggest a correlation between IKK3 and the NF- κ B site of the IL-8 promoter that has previously been identified as an endogenous NF- κ B binding site, further suggesting that IKK3 plays an important role in controlling the NF- κ B site of the IL-8 promoter. These results lead to the conclusion that IKK3 is an important regulator of IL-8 gene regulation and thus activates genes that are important for the inflammatory diseases (see Table 1 below).

10 **Table 1**
Differences between IKK1, 2 and IKK3

	IKK α , β (also known as IKK1 & IKK2)	IKK3
Expression (mRNA)	Constitutive	Inducible by IL-1 and TNF- α
Source for in vitro phosphorylation	Mammalian and Insect cells	Mammalian and Bacterial cells
Spectrum	Unknown	IL-8, IL-6 and RANTES
Substrate Selectivity	I κ B α > I κ B β	I κ B α I κ B β > I κ B α
Enzymatic activity	Need for IL-1 or TNF alfa stimulation	No need for stimulation

15 Using a computer homology analysis we have now identified a novel kinase, termed IKK4, that is 49% similarity with IKK3, 25% identical to IKK1 and 24% identical to IKK2, at the amino acid level. The overexpression of IKK4 leads to the activation of the IL-8 reporter gene via NF- κ B signalling pathway. We found that IKK4 is able to phosphorylate I κ B family proteins using immunoprecipitation assays, and directly phosphorylate I κ B β in vitro using a GST-pull down assay. These results suggest that IKK4 activates the IL-8 gene as well as some other inflammatory related gene.

20 Accordingly this invention provides a novel isolated kinase protein, referred to herein as IKK4.

Nucleotide sequence of IKK4 reveals a 2187 bp open reading frame which encodes a 729 amino acid protein (see SEQ.I.D.NO:1). At the amino acid level, IKK4 is 49 % identical to IKK3, and 25% identical to IKK1 and 24% identical to IKK2. On the other hand, IKK1 has a 52% identity to IKK2. The amino acid sequence of IKK4 revealed that it has a potential kinase domain, though IKK3 has two leucine zippers, and IKK1/IKK2 have one leucine zipper as reported previously. IKK1 and IKK2 have an HLH domain at the C-terminal region, however, we are unable to find a typical HLH domain, which were found in IKK1 and IKK2 (Figs. 3 and 4). The kinase domain of IKK3 and IKK4 have 73% identity at the amino acid level. In addition, two domains in IKK3 and IKK4 were found similarity in the amino acid level. We termed these regions as HR1 and HR2. The IKK4 HR1 region (amino acids 300-450) and IKK3 HR1 region (amino acids, 300-450) are 43% identical at the amino acid level. The IKK4 HR2 region (amino acids, 562-609) and IKK3 HR2 region (amino acids, 552-600) are 50% identical at the amino acid level.

One aspect of the invention therefore provides an isolated IKK4 kinase protein or a variant thereof. The amino acid sequence of this isolated IKK4 kinase protein is shown in SEQ I.D.No: 1.

By the term "isolated" we mean that the protein herein exists in a physical milieu distinct from that in which it occurs in nature. For example, the protein maybe substantially isolated with respect to the complex cellular milieu with which it is normally associated with. The absolute level of purity is not critical and maybe readily determined by the skilled person according to the use to which the protein is put.

Included within the invention are variants of the IKK4 kinase protein. Such variants include fragments, analogues, derivatives and splice variants. The term "variant" refers to a protein or part of a protein which retains substantially the same biological function or activity as IKK4.

Fragments can include a part of IKK4 which retains sufficient identity of the original protein to be effective for example in a screen. Such fragments may be probes such as the ones described hereinafter for the identification of the full length protein. Fragments may be fused to other amino acids or proteins or may be comprised within a larger protein. Such a fragment may be comprised within

a precursor protein designed for expression in a host. Therefore, in one aspect the term fragment means a portion or portions of a fusion protein or polypeptide derived from IKK4.

5 Fragments also include portions of IKK4 characterised by structural or functional attributes of the protein. These may have similar or improved chemical or biological activity or reduced side-effect activity. For example, fragments may comprise an alpha, alpha-helix or alpha-helix-forming region, beta sheet and beta-sheet-forming region, turn and turn-forming regions, coil and coil-forming
10 regions, hydrophilic regions, hydrophobic regions, amphipathic regions (alpha or beta), flexible regions, surface-forming regions, substrate binding regions and regions of high antigenic index.

15 Fragments or portions may be used for producing the corresponding full length protein by peptide synthesis.

20 Derivatives include naturally occurring allelic variants. An allelic variant is an alternate form of a protein sequence which may have a substitution, deletion or insertion of one or more amino acids, which does not substantially alter the function of the protein. Derivatives can also be non-naturally occurring proteins or fragments in which a number of amino acids have been substituted, deleted, added, rearranged or modified. Proteins or fragments which have at least 70% identity to IKK4 are encompassed within the invention. Preferably, the identity is at least 80%, more preferably at least 90% and still more preferably at least or greater than 95% identity for example 97%, 98% or even 99% identity to IKK4.

25 Analogues include but are not limited to precursor proteins which can be activated by cleavage of the precursor portion to produce an active mature protein or a fusion with a compound such as polyethylene glycol or a leader/secretary to aid purification.

30 A splice variant is a protein product of the same gene, generated by alternative splicing of mRNA, that contains additions or deletions within the coding region (Lewin N (1995) *Genes V* Oxford University Press, Oxford, England). The

present invention covers splice variants of the IKK4 kinase protein that occur naturally and which may play a role in the control of inflammation.

5 The protein or variant of the present invention may be a recombinant protein, a natural protein or a synthetic protein, preferably a recombinant protein.

10 A further aspect of the invention provides an isolated (as defined *supra*) nucleotide sequence which encodes a mammalian IKK4 protein as described above, or a variant thereof. Also included within the invention are anti-sense nucleotides or complementary strands.

15 Preferably, the nucleotide sequence encodes the rat, murine or human IKK4 protein. The nucleotide sequence preferably comprises the sequence of the coding portion of the nucleotide sequence shown in SEQ I.D NO: 2.

20 A nucleotide sequence encoding an IKK4 protein of the present invention may be obtained from a cDNA or a genomic library derived from the human fetus Marathon-Ready cDNA (Clonetech).

25 The nucleotide sequence may be isolated from a mammalian cell (preferably a human cell), by screening with a probe derived from the rat, murine or human IKK4 sequence, or by other methodologies known in the art such as preliminary chain reaction (PCR) for example on genomic DNA with appropriate oligonucleotide primers derived from or designed based on the rat, murine or human IKK4 sequence and/or relatively conserved regions of known IKK3 proteins. A bacterial artificial chromosome library can be generated using rat or human DNA for the purposes of screening.

30 The nucleotide sequence of the present invention may be in form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the IKK4 protein or variant thereof may be identical to the coding sequence set forth in SEQ.I.D. NO:2, or maybe a different coding

sequence which as a result of the redundancy or degeneracy of the genetic code, encodes the same protein as the sequences set forth therein.

A nucleotide sequence which encodes an IKK protein may include:

5

a coding sequence for the full length protein or any variant thereof, and additional coding sequence such as a leader or secretory sequence or a pro-protein sequence; a coding sequence for the full length protein or any variant thereof (and optionally additional coding sequence) and non-coding sequences, such as introns or non-coding sequences 5' and/or 3' of the coding sequence for the full length protein. The invention also provides nucleotide variants, analogues, derivatives and fragments which encode IKK4. Nucleotides are included which preferably have at least 70% identity over the entire length to IKK4. More preferred are those sequences which have at least 80% identity over their entire length to IKK4. Even more preferred are polynucleotides which demonstrate at least 90% for example 95%, 97%, 98% or 99% identity over their entire length to IKK4

20

The present invention also relates to nucleotide probes constructed from the nucleotide sequence of an IKK protein or variant thereof. Such probes could be utilised to screen a cDNA or genomic library to isolate a nucleotide sequence encoding an IKK4 protein. The nucleotide probes can include portions of the nucleotide sequence of the IKK4 protein or variant thereof useful for hybridising with mRNA or DNA in assays to detect expression of the IKK4 protein or localised its presence on a chromosome using for example fluorescence in situ hybridisation (FISH).

25

The nucleotide sequences of the invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the protein of the present invention such as hexa-histidine tag or hemagglutinin (HA) tag, Myc-tag, T7-tag, double MYC-tag, double HA-tag and double T7-tag expression vectors or allows determination in screening assays of effective blockage of IKK4 or it's modulation.

Nucleotide molecules which hybridise to IKK4 or to complementary nucleotides thereto also form part of the invention. Hybridisation is preferably under stringent hybridisation conditions. One example of stringent hybridisation conditions which is sometimes used is where attempted hybridisation is carried 5 out at a temperature of from about 35°C to about 65°C using a salt solution which is about 0.9 mol. However, the skilled person will be able to vary such conditions as appropriate in order to take into account variables such as probe length, base composition, type of ions present etc. The nucleotide sequence of the present invention may be employed for producing the IKK4 protein or variant 10 thereof by recombinant techniques. Thus, for example the nucleotide sequence may be included in any one of a variety of expression vehicles or cloning vehicles, in particular vectors or plasmids for expressing a protein, such vectors include chromosomal, non-chromosomal and synthetic DNA sequences. Examples of suitable vectors include derivatives of bacterial plasmids: phage 15 DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA and viral DNA. However, any other plasmid or vector may be used as long as it is replicable and viable in the host.

More particularly, the present invention also provides recombinant constructs 20 comprising one or more of the nucleotide sequences as described above. The constructs comprise an expression vector, such as a plasmid or viral vector into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment the construct further comprises one or more regulatory sequences to direct messenger mRNA 25 synthesis, including, for example a promoter operably linked to the sequence. Suitable promoters include: CMV, LTR, actin or SV40 promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector may contain an enhancer and a ribosome binding site for translation initiation and transcription terminator.

30 Large numbers of suitable vectors and promoters/enhancers, will be known to those of skill in the art, but any plasmid or vector, promoter/enhancer may be used as long as it is replicable and functional in the host.

Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts include mammalian expression vectors, insect expression vectors, yeast expression vectors, bacterial expression vectors and viral expression vectors and are described in Sambrook *et al*, Molecular Cloning: A 5 Laboratory Manual, 2nd Edition, Cold Spring Harbor, NY. (1989). The vector may also include appropriate sequences for selection and/or amplification of expression. For this the vector will comprise one or more phenotypic selectable/amplifiable markers, such markers are also well known to those skilled in the art.

10 In a further embodiment, the present invention provides host cells capable of expressing a nucleotide sequence of the invention, the host cell can be, for example, a higher eukaryotic cell, such as mammalian cell or a lower eukaryotic cell, such as a yeast cell or a prokaryotic cell such as a bacterial cell. Suitable 15 prokaryotic hosts for transformation include *E-coli*. Other examples include viral expression vectors, insect expression systems and yeast expression systems.

Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

20 The IKK4 protein is recovered and purified from recombinant cell cultures by methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, and ion or cation exchange chromatography, phosphocellulose chromatography and lecitin chromatography. Protein refolding steps may be 25 used, as necessary, in completing configuration of the mature protein. Finally high performance liquid chromatography (HPLC) can be employed for final purification steps.

30 The present invention also provides antibodies specific for the IKK4 protein. The term antibody as used herein includes all immunoglobulins and fragments thereof which contain recognition sites for antigenic determinants of proteins of the present invention. The antibodies of the present invention may be polyclonal or preferably monoclonal, may be intact antibody molecules or fragments containing the active binding region of the antibody, e.g. Fab or (Fab)₂. The present invention also includes chimaeric, single chain and 35

humanised antibodies and fusions with non-immunoglobulin molecules. Various procedures known in the art may be used for the production of such antibodies and fragments.

5 The proteins, their variants especially fragments, derivatives, or analogues thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. Antibodies generated against the IKK4 protein can be obtained by direct injection of the polypeptide into an animal, preferably a non-human. The antibody so obtained will then bind the protein itself. In this 10 manner, even a sequence encoding only a fragment of the protein can then be used to generate antibodies binding the whole native protein. Such antibodies can be used to locate the protein in tissue expressing that protein.

15 The antibodies of the present invention may also be of interest in purifying an IKK4 protein and accordingly there is provided a method of purifying an IKK4 protein or any portion thereof which method comprises the use of an antibody of the present invention.

20 The present invention also provides methods of identifying modulators of the IKK4 protein. Screens can be established for IKK4 enabling large numbers of compounds to be studied. High throughput screens may be based on ^{14}C guanidine flux assays and fluorescence based assays as described in more detail below. Secondary screens may involve electrophysiological assays utilising patch clamp technology or two electrode voltage clamps to identify small 25 molecules, antibodies, peptides, proteins or other types of compounds that inhibit, block, or otherwise interact with the IKK4 protein. Tertiary screens may involve the study of the modulators in well characterised rat and mouse models of inflammation. These models of inflammation include, but are not restricted to inflammatory models (murine) atopic dermatitis models (murine and rat), repeated-induced type dermatitis model (murine) and allergic asthma models 30 (murine and guinea pig). For example, screens may be set up based on an in vitro phosphorylation system using bacterially expressed IKK4 proteins (see Example 3 and Figure 12). This system may be used to screen for modulators of the IKK4 kinase activity and then subsequently testing the effect of potential 35 modulators of IKK4 on gene expression, specifically the expression of IL-8 using

cell based assay systems. Finally the efficacy of these modulators in relation to inflammatory or allergic diseases may be tested on models of inflammation.

The invention therefore provides a method of assaying for a modulator comprising contacting a test compound with the IKK4 protein and detecting the activity or inactivity of the IKK4 protein. Preferably, the methods of identifying modulators or screening assays employed transformed host cells that express the IKK4 protein. Typically, such assays will detect changes in the activity of the IKK4 protein to the test compound, thus identifying modulators of the IKK4 protein.

Modulators of the present invention maybe an agonist, antagonist or mimetic of IKK4 activity.

In general, a test compound is added to the assay and its effect on IKK4 is determined or the test compound's ability to competitively bind to the IKK4 is assessed. Test compounds having the desired effect on the IKK4 protein are then selected.

IL-8 is involved in diseases involving inflammation and allergies. Specifically, asthma, atopic dermatitis, arthritis, rheumatoid arthritis, systemic lupus erythematosus, LPS - induced contact dermatitis, glomerulonephritis, gout and other inflammation-related diseases.

The invention therefore provides a modulator of a protein or a variant thereof as described above identifiable by a method described above for use in therapy. The invention further provides use of a modulator of an IKK4 protein optionally identifiable by a method described above for the manufacture of an anti-inflammatory medicament. Moreover the invention provides a method of treatment which comprises administering to a patient an effective amount of a modulator of a protein as described above. More specifically, the invention provides a method of treating diseases related to inflammation, such as asthma, atopic dermatitis, arthritis, rheumatoid arthritis, systemic lupus erythematosus, LPS - induced contact dermatitis, glomerulonephritis and gout.

Complementary or anti-sense strands of the nucleotide sequences as herein above defined can be used in gene therapy. For example, the cDNA sequence of fragments thereof could be used in gene therapy strategies to down regulate the IKK4 protein. Anti-sense technology can be used to control gene expression 5 through triple-helix formation of anti-sense DNA or RNA, both of which methods are based on binding of a nucleotide sequence to DNA or RNA.

A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the product of the 10 sodium channel. The anti-sense RNA oligonucleotide hybridises to the messenger RNA *in vivo* and blocks translation of the messenger RNA into the IKK4 protein.

15 The regulatory regions controlling expression of the IKK4 protein could be used in gene therapy to control expression of a therapeutic construct in cells expressing the IKK4 protein.

Figures**Brief Description of the Figures:****Figure 1**

5 Outside factors stimulating expression of NF- κ B as well as the effect of NF- κ B on various biological events.

Figure 2

Regulation of NF- κ B activity.

10

Figure 3

Schematic representation of IKK alpha, beta, IKK3 and IKK4 (KD = kinase domain; LZ = leucine zipper, HLH = helix-loop-helix). IKK3 is 25% identical to IKK1 and 24% identical to IKK2 at the amino acid level. IKK α has a 52% identity to IKK β at the amino acid level.

Figure 4

Northern blot analysis;

20 The human tissue filter for the northern blot (gene hunter, TOYOBO) was probed with the IKK4 specific primers.

Figure 5

In vitro phosphorylation of I κ B proteins by IKK4.

25

Figure 6

IKK4 directly phosphorates TRIP9.

The bacterially expressed GST-IKK4 were incubated with the bacterially expressed GST, GST-TRIP9, -TRIP9/AA and [γ ³²P] ATP for 30 min at 30°C. 30 Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography

Figure 7

IKK4 controls an essential step in NF- κ B signalling pathway.

Example 1 Materials and methods**Cells and transfection**

HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with
5 10% fetal calf serum. DNA transfection into cells was performed via DOSPER
transfection according to the manufacturer's instructions.

Vector construction

Two EST cDNA fragments (AA361478 and AA173512), similar to IKK3 were
10 derived from one cDNA. The full length IKK4 cDNA was obtained by PCR from
the human Jurkat cell line using Marathon cDNA Amplification kit (Clonetech).
The 5' half fragment (5' primer AP1 and 3' primer G198) and 3' half fragment (5'
primer G197 and AP1) were amplified by PCR and digested with Nhe I. The
resulting fragment was subcloned into pCR2.1-TOPO vector. To attach a Not I
15 site at the both ends of the cDNA, the cDNA was amplified by PCR with 5'
primer G205 and 3' primer G213. The cDNA was subcloned into a pCR2.1-
TOPO vector.

G197: 5'-ACGAAGGGCGACGCTTAGTCTTAGAAC-3'

G198: 5'-GTGCGTCATAGCTTTGTGGCATGGT-3'

20 G205: 5'-CCCCCGCGGCCACCATGCAGAGCACTTCTAATCATCTG-3'

G213: 5'-CCCCCGCGGCCCTAAAGACAGTCAACGTTGCGAAGGCC-3'

The cDNA fragment was digested with *Not*I and the fragment was subcloned
into pGEX-4T (Pharmacia).

25 All PCR-derived sequences used in this study were confirmed by the Sanger
method.

Example 2**Northern blot analysis****Expression of IKK4**

30 To test the expression of IKK4 in human tissues, we performed Northern blot
analysis. The IKK4 expression was detected in the Brain, Liver, Pancreas,
Placenta and Lung, but not in the Heart (Fig. 6).

Example 3**In vitro phosphorylation**

HeLa cells were transiently expressed with the double T7-tagged IKK4 (DT7-IKK4) expression vector. Thirty-six hours after transfection, cells were prepared

5 by lysis with TNE buffer (10 mM Tris-HCl, pH 7.8; 1% NP-40, 0.15 M NaCl; 1 mM EDTA; 10 mM NaF, 2 mM Na₃VO₄, 10 mM PNPP and complete) and the IKK4 protein was immunoprecipitated with anti-T7 antibody. Purified DT7-IKK4 was used for in vitro kinase reactions with bacterially expressed GST, GST- $\text{I}\kappa\text{B}\alpha$ (1-54), - $\text{I}\kappa\text{B}\beta$ (1-44), - $\text{I}\kappa\text{B}\varepsilon$ (140-244), -TRIP9 (1-44) and [γ -³²P] ATP. The 10 alanine-substitution mutants GST- $\text{I}\kappa\text{B}\alpha$ ($\text{I}\kappa\text{B}\alpha$ /AA), - $\text{I}\kappa\text{B}\beta$ ($\text{I}\kappa\text{B}\beta$ /AA), -TRIP9 (1-44, AA), - $\text{I}\kappa\text{B}\varepsilon$ ($\text{I}\kappa\text{B}\varepsilon$ /AA1 and $\text{I}\kappa\text{B}\varepsilon$ /AA2) were used as control proteins. Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography.

15 In the case of direct phosphorylation of $\text{I}\kappa\text{B}$ by IKK4, the bacterially expressed GST-DT7-IKK4 was used as a kinase. 250 ng of purified kinase solution was used for in vitro kinase reactions with a 500 ng of bacterially expressed GST, GST-TRIP9 (1-44), -TRIP (1-44, AA) and [γ -³²P] ATP. Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography.

20

Results:

To test whether IKK4 is able to phosphorylate $\text{I}\kappa\text{Bs}$, we transfected HeLa cells with the double T7-tagged IKK4 expression vector. Thirty-six hours after transfection, IKK4 proteins were immunoprecipitated with anti-T7 antibody.

25 Purified IKK4 was used for in vitro kinase reactions, containing [γ -³²P] ATP and bacterially expressed GST, GST- $\text{I}\kappa\text{B}\alpha$ (1-54 a.a.), - $\text{I}\kappa\text{B}\beta$ (1-44 a.a.), - $\text{I}\kappa\text{B}\varepsilon$ (140-244 a.a.), and -TRIP9 (1-44 a.a.).

30 The immunoprecipitates of the double T7-tagged IKK4 preferentially phosphorylate GST- $\text{I}\kappa\text{B}\beta$ rather than GST- $\text{I}\kappa\text{B}\alpha$ and $\text{I}\kappa\text{B}\varepsilon$, while the immunoprecipitates did not phosphorylate GST in vitro (Fig. 7). Previously, it has been reported that residues Ser 32/Ser36 in $\text{I}\kappa\text{B}\alpha$ and Ser19/Ser23 in $\text{I}\kappa\text{B}\beta$ become phosphorylated upon TNF- α or IL- α/β stimulation (Brockman et al., 1995; Brown et al., 1995; Traenchnner et al., 1995; Whiteside et al., 1995; DiDonato et al., 1996). To test whether these residues are phosphorylated by

IKK4, we mutated the residues in $\text{I}\kappa\text{B}\alpha$ to alanine. The corresponding residues of $\text{I}\kappa\text{B}\beta$ and $\text{I}\kappa\text{B}\epsilon$ were also mutated to alanine. The alanine-substitution mutants GST- $\text{I}\kappa\text{B}\alpha$ (1-54, AA), - $\text{I}\kappa\text{B}\beta$ (1-44, AA), were not phosphorylated at all (Fig. 7, lanes 3, 5). On the other hand, the alanine mutants of GST- $\text{I}\kappa\text{B}\epsilon$ (140-244, AA1 and AA2) were partially phosphorylated (Fig. 7, lanes 7 and 8).

These data suggest that IKK4 is involved in the $\text{I}\kappa\text{B}$ phosphorylation. However, it is still unclear whether IKK4 directly phosphorylates $\text{I}\kappa\text{Bs}$ or requires some other molecules to modify the $\text{I}\kappa\text{Bs}$. We next examined whether IKK4 directly phosphorylates $\text{I}\kappa\text{Bs}$ using a GST-pull down assay. We constructed GST-DT7-IKK4 and expressed the GST-IKK4 protein in *E. coli*. The affinity purified GST-IKK4 was used for the in vitro phosphorylation assay. The bacterially expressed GST, GST-TRIP9 or GST-TRIP9/AA were incubated with GST-IKK4 and [γ -³²P] ATP. The proteins were separated by SDS-PAGE, stained with Coomassie blue and the gel was analyzed by autoradiography. Figure 8 shows that GST-IKK4 phosphorylates GST-TRIP9 but not GST and GST-TRIP9/AA. These results indicate that IKK4 directly phosphorylate serine 19 or 23 of $\text{I}\kappa\text{B}\beta$.

IKK4 regulates the NF- κB site of IL-8

Previously, we reported that IKK3 is able to control the IL-8 reporter gene via the NF- κB binding site. To test whether IKK4 regulates the NF- κB site of IL-8, DT7-IKK4 was transiently expressed in the human 293T cells with the IL-8 reporter gene. Transient expression of IKK4 activates the IL-8 reporter gene, while IKK4 is unable to activate the mutated reporter gene that contains a mutation at the NF- κB site of the IL-8 promoter (Fig. 9). These observations indicate that IKK4 is one of a critical kinases for the IL-8 gene regulation via the NF- κB site.

C L A I M S

1. The protein having the amino acid sequence in Seq. I.D No. 1, or a variant thereof.

5

2. An IKK4 kinase protein or variant thereof according to claim 1 for use in a method for screening for agents with anti-inflammatory activity.

10

3. A nucleotide sequence encoding the protein of claim 1 or a variant thereof, or a nucleotide sequence which is complementary thereto.

15 4. A nucleotide sequence encoding the protein of claim 1 as shown in Seq. I.D No. 2, or a variant thereof, or a nucleotide sequence which is complementary thereto.

5

5. The nucleotide sequence of either claim 3 or 4, which is a cDNA sequence.

6. A nucleotide sequence that hybridises to any part of a nucleotide strand referred to in either of claims 3 to 5.

20

7. An expression vector comprising a nucleotide sequence according to any one of claims 3 to 6, which is capable of expressing a IKK4 kinase protein or a variant thereof.

25

8. A stable cell line comprising a vector according to claim 7.

9. A cell line according to claim 8 which is a Hela cell line.

10. An antibody specific for a protein as claimed in claim 1.

30

11. A method for identification of a compound which exhibits IKK4 kinase modulating activity, comprising contacting a IKK4 kinase protein according to claims 1 or 2 with a test compound and detecting modulating activity or inactivity.

12. A compound which modulates the protein of claim 1, identifiable by a method according to claim 11.
- 5 13. A method of treatment or prophylaxis of a disorder which is responsive to modulation of IKK4 kinase activity in a mammal, which comprises administering to said mammal an effective amount of a compound identifiable by the method according to claim 11.
- 10 14. Use of a compound identifiable by the method according to claim 11 in a method of formulating a medicament for treatment or prophylaxis of a disorder which is responsive to the modulation of IKK4 kinase activity in a mammal.
- 15 15. A method of producing an IKK4 kinase protein comprising introducing into an appropriate cell line a suitable vector or vectors comprising a nucleotide sequence encoding for IKK4 or variants thereof, under conditions suitable for obtaining expression of the protein or variants.




FIG. 1




FIG. 2

3/12




FIG. 3

4/12





FIG. 4

5/12



In vitro phosphorylation of I κ B proteins by IKK4.

HeLa cells were transiently expressed with the double T7-tagged IKK4 expression vector. Thirty-six hours after transfection, IKK4 proteins were immunoprecipitated with anti-T7 antibody. Purified DT-IKK4 was used for in vitro kinase reactions with bacterially expressed GST, GST- $\text{IkB}\alpha$ - $\text{IkB}\alpha\text{AA}$, $\text{IkB}\beta$ -TRIP9/AA, $\text{IkB}\epsilon$, $\text{IkB}\epsilon\text{/AA1}$ and $\text{IkB}\epsilon\text{/AA2}$ and [γ - ^{32}P] ATP. Proteins were separated by SDS-PAGE, stained with Coomassie blue and analyzed by autoradiography.

FIG. 5

6/12




FIG. 6

7/12




FIG. 7

8/12

IKK1	MERPPGLRPAGGPWEMRERLGTGGFCNVCLYQHRELDLKIAIKSCRLELSTKNERWCH	60
IKK2	MSWSPSLTTQTCGAWEMKERLGTGGFCNVIRWHNQETCEQIAIKQCRQELSPRNRRERWCL	60
IKK3	-----MQSTANYLWHTDDLLGQGATASVYKARNKKSGELVAVKVFNTTSYLRPREVQVR	54
IKK4	-----MQSTSNNHLWLLSDILGQCATANVFRGRHKKTGDLFAIKVFNNSFLRPVDVQMR	54
IKK1	EQIQIMKKLNHANVVKACDVPEELN-LLJHDVPLLAAMEYQSGGDLRKLLNKPENCGLKES	119
IKK2	EQIQIMRRRLTHPNVVAARDVPECMQNLAPNDLPLLAMEYQCGGDLRKYLNQFENCCGLREG	120
IKK3	EFEVLRLKLNHQNIVKLFAVEETGG----SRQKVLMEMEYCSSGSLLSVLESPENAFGLPED	110
IKK4	EFEVLKKLNHKNIVKLFIAEEFTT----TRHKVLMIFCPCCGSLYTVEEPSNAYGLPES	110
IKK1	QILSLLSDICSGIRYLHENKIIHDLKPENIVLQDVG-GKUHKIIDLGYAKDVDQGSCLC	178
IKK2	AILTLLSDIASALRYLHENRUIHDLKPENIVLQQGE-QRLJHKIIDLGYAKELDQGSCLC	179
IKK3	EFLVVLRCVVGAGMNHRENGIVHRDIKPGNIMRLVGEEGQSIYKLTDFAARELDDDEKF	170
IKK4	EFLIVLRDVVGAGMNHRENGIVHRDIKPCNMRVIGEDGQSVYKLTDFAARELEDDEQF	170
IKK1	TSFVCTLQYLAPELFE-----NKPYATVDYWSFGTMVFECIAGYRPFHLHLQP---	227
IKK2	TSFVGTQYLAPELLE-----QQKYTVTVDYWSFGTIAFECITCFRPFLPNWQP---	228
IKK3	VSVYGTTEEYLHPDMYERAVLRKPQQKAFGVTVDLWSIGVTLYHAATGSLPFIPFGPRRN	230
IKK4	VSLYCTTEEYLHPDMYERAVLRKDHQKKYGATV рDLWSICVTFYHAATGSLPFRFEGPRRN	230
IKK1	--FTWHEKIKKKDPKCIFACEEMSCEVRFSSHLQPQNSLCSLIVEPMENWLQLMLNWDPQ	285
IKK2	--VQWHISKVRQKSEVDIVVSCDLNCTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHP	286
IKK3	KEIMYRITTEKPGAGAQRRENCPLEWSYTLITCQLSCLQSQLVPILANILEVE--	288
IKK4	KEVMYKIITGKPSCAISCVQKAENGPIDWSCDMPVSCSLSRGLQVLLTPVLANILEAD--	289
IKK1	QRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKILSFLPPDESLHSLQSRIERET	345
IKK2	QRG--TDPTYGPNGCFKALDDILNLKLVHILNMTGTIHTYPVTEDESLSQLKARIQQDT	344
IKK3	QAK----CWGFDQFFAETSDILQRVVVHVFSLSQAVLHHIYIHAHNTIAIFQEAVHKQT	343
IKK4	QEK----CWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYHSYNTATIFHELVYKQT	343
IKK1	GINTGSQELLSETC-ISLDPRKPASQCVLDC---VRGCDSYMVLFDKSKTVYEGPFAS	400
IKK2	GIPEDQELLQEAG-LALIPDKPATQCISDGKLNEGHTLMDLVFLFDNSKITYETQISP	403
IKK3	SVAPRHQEYLFEGHLCVLEPSV-SAQHIAHT-----TASSPLTLFSTA---IPKGLAF	392
IKK4	KTISSNQELIYEGRRLVLEPGR-LAQHFPKT-----TEENPIFVVSRE---PLNTIGI	392
IKK1	RSLSDCVNYIVQDSKIQLPNQLRKVWAЕAVHYSGLKEDYSRLFQCQRAAMLSLLRYNA	460
IKK2	RPQPESVSCILQEPKRNLAFFQLRKVWQVWHSIQT-LKEDCNRLQQGQRAAMMNLLRNNS	463
IKK3	RDPALDVPKFVPKVDLQADYNTAKGVLCAGYQALRIARALLD---GQELMFRCLHWVME	448
IKK4	YEKISLPKVHPRYLDGDASMAKATGVVCYACRIASTLL---YQELMRKGIRWLIE	448

FIG. 8

9/12

IKK1	NLT K M K N T L I S A S Q Q L K A K L E F F H K S I Q L D L E R Y S E Q M T Y G I S S E K M L K A W K E M E E K A I H	520
IKK2	C L S K M K N S M A S M S Q Q L K A K L D F F K T S I Q I D L E K Y S E Q T E F G I T S D K L L L A W R E M E Q A V E L	523
IKK3	V L Q A T C R R T L E V A R T S L L Y L S S L G T E R F S S V A C T P E I Q E L K A A A E L R S R L R T L A E V L S R	508
IKK4	L I K D D Y N E T V H K K T E V V I T L D F C I R N I E K T V K V Y E K L M K I N L E A A E L G - E I S D I H T K L L R	507
IKK1	Y A E V G V I G Y L E D Q I M S L H A E I M E L - - - - - Q K S P Y G - R R Q G D L M E S L E Q R A I D L Y K Q	570
IKK2	C G R E N E V K L L V E R M M A L Q T D I V D L - - - - - Q R S P M G - R K Q G G T L D D L E E Q A R E L Y R R	573
IKK3	C S Q N - - I T E T Q E S L S S L N R E L V K S - - - - - R D Q V H E - D R S I Q Q I Q C C L D K M N F I Y K Q	556
IKK4	L S S S - - Q G T I E T S L Q D I D S R L S P C G S L A D A W A H Q E C T H P K D R N V E K L Q V I L N C M T E I Y Y Q	565
IKK1	L K H R P S D - H S Y S D S T E M V K I V H T V Q S Q D R V L K E L F G H L S K L L G C K Q K I I D L L P K V E A V L	629
IKK2	L R E K P R D Q R T E G D S Q E M V R L L L Q A I Q S F E K K V R V I Y T Q L S K T V V C K Q K A L E L L P K V E E V V	633
IKK3	F K K S R M R - P G L G Y N E E Q - - - I H K L D K V N F S H L A K R L L Q V F Q E E C V Q K Y Q A S L V T H C K R M	611
IKK4	F K K D K A E - R R L A Y N E E Q - - - I H K F D K Q K L Y Y H A T K A M T H F T D E C V K K Y E A F L N K S E E W I	620
IKK1	S N I K E A D N T V M F M Q G K R Q K E I W H L L K I A C T Q S S A R S L V G S S L E G A V T P Q T S A W L P P T S A E	689
IKK2	S L M N E D E K T V V R I L Q E K R Q K E L W N L L K I A C S K - - V R G P V S G S P D - - - S M N A S R L S Q P C Q L M	688
IKK3	R V V H E T R N H L R L V G C S V A C N T E A Q G V Q E S L S K L L E E L S H Q L L Q D R A K G A Q A S P P I A P Y	671
IKK4	R K M L H L R K Q L L S L T N Q C F D I E E V S K Y Q E Y T N E L Q E T L P Q K M F T A S S - G I K H T M T P I Y P S	679
IKK1	H D H S L S C V V T P Q D G E T S A Q M I E E N L N C L C H L S T I I H E A N E E Q G N S M M N L D W S W L T - - - -	745
IKK2	S Q P S T A S N S L P E P A K K S E E L V A E A H N L C T L L E N A I Q D T V R E Q D Q S F T A L D W S W L Q T E E E E	748
IKK3	P S P T R K D L L L H - - - M Q E L C E G M K L L A S D L L D N N R - - I I E R L N R V P A P P D V - - - - -	716
IKK4	- S N T L V E M T L C - - - M K K L K E E M E G V V K E L A E N N H - - I L E R F G S L T M D G G L R N V D C L - - 729	
IKK1	-----	
IKK2	H S C L E Q A S	756
IKK3	-----	
IKK4	-----	

Predicted amino acid sequence of IKK4.

The potential kinase domain (KD) and helix-loop-helix (HLH) are boxed. The potential leucine zipper are underlined. Asterisks and dots indicate identical and similar amino acids, respectively. Numbers in the right indicate position of the amino acids.

FIG. 9

10/12

ikk4.seq Length: 3372

1 GTTGTAAAAC GACGGCCAGT GAATTGTAAT ACCACTCACT ATAGCCCCAA
51 TTGGGCCCTC TAGATGCATG CTCGAGCGGC CGCCAGTGTG ATGGATATCT
101 GCAGAATTG CCGTTCCATC CTAATACGAC TCACTATAGG GCTCGAGCGG
151 CCGCCCGGGC AGCTCCAGGG CTTGCGAAGC CGGAAGTGTG CTGAGTCTCG
201 AGGAGGCCGC GGAGGCCGC CGGCGGTGGC GCGCGGAGA CCCGGCTGGT
251 ATAACAAGAG GATTCCCTGA TCCAGCCAAG ATGCAGAGCA CTTCTAATCA
301 TCTGTGGCTT TTATCTGATA TTTTAGGCCA AGCAGCTACT GCAAATGTCT
351 TTCGTGGAAG ACATAAGAAA ACTGGTGATT TATTTGCTAT CAAACTATT
401 AATAACATAA GCTTCCTTCG TCCAGTGGAT GTTCAAATGA GAGAATTG
451 ACTGTTGAAA AACTCAATC AAAAAATAT TGTCAAATTG TTTGCTATTG
501 AAGAGGAGAC AACACAAGA CATAAAGTAC TTATTATGGA ATTTTGTCCA
551 TGTGGGAGTT TATACACTGT TTTAGAAGAA CCTTCTAATG CCTATGGACT
601 ACCAGAATCT GAATTCTAA TTGTTTGCG AGATGTGGTG GGTGGAATGA
651 ATCATCTACG AGACAATGGT ATAGTGCACC GTGATATCAA GCCAGGAAAT
701 ATCATGCGTG TTATAGGGGA AGATGGACAG TCTGTGTACA AACTCACAGA
751 TTTTGGTCCA GCTAGAGAAT TAGAAGATGA TGAGCACTTT GTTCTCTGT
801 ATGGCACAGA AGAATATTC CACCTGATA TGTATGAGAG AGCAGTCCTA
851 AGAAAAGATC ATCAGAAGAA ATATGGAGCA ACAGTTGATC TTTGGACCAT
901 TCGGGTAACA TTTTACCATG CAGCTACTGG ATCACTGCCA TTTAGACCT
951 TTGAACGGCC TCGTAGGAAT AAAGAAGTGA TGTATAAAAT AATTACAGGA
1001 AAGCCTCTG GTGCAATATC TCGAGTACAG AAAGCAGAAA ATGGACCAAT
1051 TGACTGGAGT GGACACATGC CTGTTCTTG CACTCTTCT CGGGGTCTTC

FIG. 10

11/12

1101 AGGTTCTACT TACCCCTGTT CTTGCAAACA TCCTTGAAGC AGATCAGGAA
1151 AAGTGTGCGG GTTTGACCA GTTTTTGCA GAAACTAGTG ATATACTTCA
1201 CCGAATGGTA ATTCACTGTT TTTCGCTACA ACAAAATGACA GCTCATAACA
1251 TTTATATACA TAGCTATAAT ACTGCTACTA TATTTCATGA ACTGGTATAT
1301 AAACAAACCA AAATTATTC TTCAAATCAA GAACTTATCT ACGAAGGGCG
1351 ACGCTTAGTC TTAGAACCTG GAAGGCTGCC ACAACATTTC CCTAAAACCA
1401 CTGAGGAAAA CCCTATATTT GTAGTAAGCC GGGAACCTCT GAATACCATA
1451 GGATTAATAT ATGAAAAAAAT TTCCCTCCCT AAAGTACATC CACGTTATGA
1501 TTTAGACGGG GATGCTAGCA TGGCTAAGGC AATAACAGGG GTTGTGTGTT
1551 ATGCCTGCAG ATTGCCAGT ACCTTACTGC TTTATCAGGA ATTAATGCCA
1601 AAGGGCATAAC GATGGCTGAT TGAATTAATT AAAGATCATT ACAATGAAAC
1651 TGTTCACAAA AAGACAGAAG TTGTGATCAC ATTGGATTC TGTATCAGAA
1701 ACATTGAAAA AACTGTGAAA CTATATGAAA ACTTGATGAA GATCAACCTG
1751 GAAGCGGCAG AGTTAGGTGA AATTCAGAC ATACACACCA AATTGTTGAG
1801 ACTTTCCAGT TCTCAGGCAA CAATAGAAC CAGTCTTCAG GATATCGACA
1851 GCAGATTATC TCCAGGTGGA TCACTGCCAG ACGCATGGGC ACATCAAGAA
1901 GGCACTCATC CGAAAGACAG AAATGTAGAA AACTACAAG TCCGTGTTAAA
1951 TTGCATGACA GAGATTTACT ATCACTTCAA AAAAGACAAA GCAGAACGTA
2001 CATTAGCTTA TAATGAAGAA CAAATCCACA AATTGATAA CCAAAACTG
2051 TATTACCATG CCACAAAAGC TATGACCCAC TTTACAGATG AATGTGTTAA
2101 AAAGTATGAG GCATTTTGA ATAAGTCAGA ACAATGGATA AGAAACATGC
2151 TTCATCTTAG GAAACACTTA TTATCGCTCA CTAATCACTG TTTTGATATT
2201 GAAGAAGAAG TATCAAAATA TCAAGAATAT ACTAATGACT TACAAGAAC

FIG. 11

12/12

2251 TCTGCCTCAG AAAATCTTCA CAGCTTCCAG TGGAATCAAACATACCATGA
2301 CCCCAATTAA TCCAAGTTCT AACACATTAG TAGAAATGAC TCTTGGTATC
2351 AAGAAATTAA AGGAACAGAT CGAACGGGTG GTTAAAGAAC TTGCTGAAAA
2401 TAACCACATT TTAGAAAGGT TTGGCTCTTT AACCATGGAT GGTGGCCTTC
2451 GCAACGTTGA CTGTCTTAC CTTCTAATA GAACTTTAAG AAAAGTTCC
2501 GTTGCACAA GAAAATAACG CTTGGGCATT AAATGAATGC CTTTATAGAT
2551 AGTCACTTGT TTCTACAATT CAGTATTGAT TGTGCTCGTGTAAATATGTA
2601 CAATATTGTA AATACATAAA AAATATACAA ATTTTGCT GCTGTGAAGA
2651 TGTAATTAA TCTTTAACAA TTTATAATTA TATCAGGAAA TTTGACCTCA
2701 GTGATCACGA GAAGAAAGCC ATGACCGACC AATATGTTGA CATACTGATC
2751 CTCTACTCTG ACTGGGGCTA AATAAGTTAT TTTCTCTGAC CGCCTACTGG
2801 AAATATTTT AAGTGGAACCC AAAATAGGCA TCCTTACAAA TCAGGAAGAC
2851 TGACTTGACA CGTTGTAAA TGGTAGAACG GTGGCTACTG TGAGTGGGA
2901 CCAGAACCGC ACCACTGTTA TACTGGATA ACAATTTT TGAGAACGGAT
2951 AAAGTGGCAT TATTTTATTAA TACAAGGTGC CCAGATCCCA GTTATCCTG
3001 TATCCATGTA ATTTCAGATG AATTATTAAG CAAACATTTT AAAGTGAATT
3051 CATTATTAAA AACTATTCA TTTTTTCCCTT TGGCCATAAA TGTGTAATTG
3101 TCATTAAT TCTAACGTCA TTTCAACTGT TTTAACGCTGT ATTTCTTAA
3151 TTCTGCTTAC TATTCATGG AAAAAAATAA ATTTCTCAAT TTTAAAAAAA
3201 AAAAAAAA AAAAAAAAGC GTTCTAGAAT TCAGCGGCCG CTGAATTCTA
3251 GACCTGCCCG GCGGGCCGCT CGAGCCCTAT AGTGAAGTCGT ATTAGGATGG
3301 AACGGCGAAT TCCAGCACAC TGGCGGCCGT TACTAGTGGATCCGAGCTCG
3351 GTACCAAGCT TGGCGTAATC AG

FIG. 12

Job : 242
Date: 7/5/2006
Time: 9:06:39 AM

seq.txt

SEQUENCE LISTING

<110> GeneSense Technologies Inc. et al.

<120> Antisense Oligonucleotides Directed To
Ribonucleotide Reductase R2 and Uses Thereof in Combination
Therapies for the Treatment of Cancer

<130> 683-134pct

<140> n/a
<141> 2005-01-12

<150> US60/535,496
<151> 2004-01-12

<150> US60/602,817
<151> 2004-08-18

<160> 105

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense oligonucleotide complementary to human
ribonucleotide reductase R2 mRNA

<400> 1
ggctaaatcg ctccaccaag

20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Control antisense oligonucleotide

<400> 2
ggctaaatcg gtccaccaag

20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Control oligonucleotide

<400> 3
acgcactcag ctagtgacac

20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
<223> AS-II-6-20 antisense oligonucleotide complementary
to human ribonucleotide reductase R2 mRNA

<400> 4
acccttccca ttggctgcgc 20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-13-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 5
gcctccgacc cttcccat 20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-14-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 6
tgcctccgac cttcccat 20

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-16-18 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 7
tgcctccgac cttccca 18

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Partially Phosphorothioated AS-II-75-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 8
cgcgcgctcc cggcccttcc 20

<210> 9
<211> 20
<212> DNA

seq.txt

<213> Artificial Sequence

<220>

<223> AS-II-75-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 9

cgcgcgtcc cggcccttcc

20

<210> 10

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-79-14 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 10

cgcgtcccg gccc

14

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-109-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 11

ccctcaactc cagcagcatt

20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-110-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 12

accctcaact ccagcagcct

20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-114-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 13

ggcgaccct cactccagca

20

<210> 14

seq.txt

<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-127-12 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 14
gcacgggcga cc 12

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-130-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 15
tggcacaggg tgcacggcg 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-134-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 16
gacggctggg acagggtgca 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-151-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 17
gagcagccag gacaggacgg 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-163-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 18
gcgaaggcaga gcgagcagcc 20

seq.txt

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-166-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 19
gcagcgaagc agagcgagca 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-185-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 20
gggagagcat agtggaggcg 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-189-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 21
cggagggaga gcatagtgga 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-201-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 22
gcgagcggga cacggaggg 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-217-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

seq.txt

<400> 23		
cgggtccgtg atgggcgcga		20
<210> 24		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-225-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 24		
agctgctgcg ggtccgtat		20
<210> 25		
<211> 14		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-253-14 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 25		
ccccttcagc ggcg		14
<210> 26		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-280-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 26		
cggcggcgtg ttctccttgt		20
<210> 27		
<211> 12		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-288-12 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 27		
cggcggcgtg tt		12
<210> 28		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-323-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
Page 6		

seq.txt

mRNA

<400> 28
tcctcgccgt cttgctggcc 20
<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-344-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 29
ccgtgggctc ctggaagatc 20
<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-362-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 30
ctgcttttagt tttcggtc 20
<210> 31
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-391-17 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 31
cggctcatcc tccacgc 17
<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-404-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 32
ggttttctct cagcagcggc 20
<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence
<220>

seq.txt

<223> AS-II-412-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 33
gcggcgaaaa ttttctctca 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-414-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 34
aagcggcgaa gttttctct 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-425-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 35
ggaagatgac aaagcggcg 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-439-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 36
atggtaatcg atggggaa 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-472-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 37
agcctctggc ttcttataca 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
<223> AS-II-494-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 38
cctcctcgac ggtccaaaag 20

<210> 39
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-496-16 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 39
tcctcgccgg tccaaa 16

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-549-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 40
tatctctcct cgggtttcag 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-579-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 41
gcaaagaaaag ccagaacatg 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-619-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 42
tcgctccacc aagttttcat 20

<210> 43
<211> 20

seq.txt

<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-634-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 43
aacttcttgg ctaaatcgct 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-667-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 44
gaagccatag aaacagcggg 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-784-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 45
gacacaaggc atcgaaa 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-798-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 46
tctgccttct tcttgacaca 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-816-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 47
atccagcgca aggcccagtc 20

seq.txt

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-861-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 48
gcaaaggcta caacacgttc 20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-890-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 49
aaccggaaaa gaaaatgcct 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-909-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 50
ggcatcagtc ctcgtttctt 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-933-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 51
ggcatcagtc ctcgtttctt 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-981-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 52
Page 11

seq.txt

20

tgtaaacct catctctgct

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1001-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 53

tcaggcaagc aaaatcacag

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1006-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 54

gaacatcagg caagcaaaat

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1023-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 55

ttgtgtacca ggtgtttgaa

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1040-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 56

ctctctccctc cgatggtttg

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1048-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

seq.txt

<400> 57		
ttctcttact ctctcctccg		20
<210> 58		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1144-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 58		
gtattgcttc attagagtgc		20
<210> 59		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1182-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 59		
cccaagttcca gcataagtct		20
<210> 60		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1197-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 60		
aaaacaccttgc taaaacccag		20
<210> 61		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1217-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 61		
caaatgggtt ctctactctg		20
<210> 62		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1224-20 antisense oligonucleotides		

seq.txt

complementary to human ribonucleotide reductase R2
mRNA

<400> 62
ataaaagtcaa atgggttctc 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1254-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 63
ttagctttc cttccagtga 20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1278-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 64
tcgcctactc tcttctcaaa 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1288-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 65
cctctgatac tcgcctactc 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1302-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 66
gacatcactc ccatcctctg 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
<223> AS-II-1335-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 67
gcatccaagg taaaagaatt 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1338-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 68
tcagcatcca aggtaaaaga 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1342-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 69
gaagtccatca tccaaaggtaa 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1345-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 70
ttagaagtca gcatccaagg 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1362-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 71
gcacatcttc agttcattta 20

<210> 72
<211> 20
<212> DNA

seq.txt

<213> Artificial Sequence

<220>

<223> AS-II-1364-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 72

gggcacatct tcagttcatt

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1381-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 73

aaaaatcagc caagtaaggg

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1390-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 74

atggaaaaaa aaaatcagcc

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1438-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 75

ttcatggtgt ggctagttgg

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> AS-II-1499-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 76

aggactggtt gtgaggtgc

20

<210> 77

seq.txt

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1517-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 77
ccagcactat aaacagacag 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1538-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 78
ttctggcaaa aggtgatact 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1560-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 79
gtaagtcaaa gccagccagg 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1581-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 80
actgccattt tcactgctat 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1659-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 81
tggctgtgct ggttaaagga 20

seq.txt

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1666-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 82
ttttaactgg ctgtgctgg 20
ataaaaatct gcgttgaagc

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1700-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 83
atataatctt gcgttgaagc 20
tatccggcc gtgagtacaa

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1768-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 84
tatccggcc gtgagtacaa 20
tatccggcc gtgagtacaa

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1773-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 85
gctattatcg ccggcgtgag 20
gctattatcg ccggcgtgag

<210> 86
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-1775-12 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

seq.txt

<400> 86		
atcgccgccc tg		12
<210> 87		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1790-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 87		
gaaacccaaat aaatcaagct		20
<210> 88		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1819-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 88		
ttagttgtca ggagaatgtt		20
<210> 89		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1976-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 89		
tggcaccaac tgactaatat		20
<210> 90		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-1989-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		
mRNA		
<400> 90		
cctgtttctt atctggcacc		20
<210> 91		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> AS-II-2009-20 antisense oligonucleotides		
complementary to human ribonucleotide reductase R2		

seq.txt

mRNA

<400> 91
gccacaggat aaaaacacaa 20
<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-2026-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 92
cccaggacac tacacaagcc 20
<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-2044-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 93
tcagaggggg cagagaatcc 20
<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-2067-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 94
tcctttatcc cacaacactc 20
<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> AS-II-2083-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 95
ccttgcgcctg agagattcct 20
<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence
<220>

seq.txt

<223> Partially Phosphorothioated AS-II-2083-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 96
ccttgccttg agagattcct 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2128-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 97
ggcccgatc acccctaaat 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2151-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 98
aaacggcttc tcacacat 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2164-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 99
gagaataaaa atgaaacggc 20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2182-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 100
cgttgaggaa aatacagtga 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

seq.txt

<220>
<223> AS-II-2229A-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 101
gctcccacat atgaaaactc 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> AS-II-2372-20 antisense oligonucleotides
complementary to human ribonucleotide reductase R2
mRNA

<400> 102
cacacaacct acttacacca 20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense oligonucleotides complementary to human
ribonucleotide reductase R2 mRNA

<400> 103
tcctggaaga tcctcctcgc 20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense oligonucleotides complementary to human
ribonucleotide reductase R2 mRNA

<400> 104
tccccacatat gagaaaactc 20

<210> 105
<211> 2500
<212> DNA
<213> Homo sapiens

<220>
<221> mRNA
<222> (1)...(2500)
<223> ribonucleotide reductase R2 mRNA

<400> 105
cccaatggga agggtcggag gcatggcaca gccaatggga agggccgggg 60
caccaaagcc aatgggaagg gccgggagcg cgccggcgcgg gagattaaa ggctgctgg 120
gtgagggggtc gcccgtgcac cctgtcccgag ccgtcctgtc ctggctgctc gctctgc 180
gctgcgcctc cactatgctc tccctccgtg tcccgctcgc gccccatcagc gaccgcgc 240
agctgcagct ctcgcccgtg aaggggctca gcttggtcga caaggagaac acgcccgcgg 300
ccctgagcgg gaccgcgtc ctggccagca agaccgcgag gaggatctc caggagccca 360

seq.txt

cggagccgaa	aactaaagca	gctgcccccg	gcgtggagga	ttagccgctg	ctgagagaaa	420
accccccgcg	cttgcacatc	ttccccatcg	agtaccatga	tatctggcag	atgtataaga	480
aggcagaggc	ttccttttgg	accggcgagg	aggttgacct	ctccaaggac	attcagcact	540
gggaatccct	gaaacccgag	gagagatatt	ttatatccca	tgttctggct	ttcttgcag	600
caagcgatgg	catagtaaat	gaaaacttgg	tggagcgtt	tagccaagaa	gttcagattt	660
cagaagcccg	ctgtttctat	ggcttccaaa	ttgccatgga	aaacatacat	tctgaaatgt	720
atagtcttct	tattgacact	tacataaaaag	atcccaaaga	aagggaattt	ctcttcaatg	780
ccattgaaac	gatgccttgc	gtcaagaaga	aggcagactg	ggccttgcgc	tggattgggg	840
acaaagaggc	tacctatggt	gaacgttttgc	tagccttgc	tgcagtggaa	ggcattttct	900
tttccggttc	ttttgcgtcg	atattctggc	tcaagaaaacg	aggactgtat	cctggccctca	960
cattttctaa	tgaacttatt	agcagagatg	agggtttaca	ctgtgatttt	gcttgcctga	1020
tgttcaaaca	cctggtacac	aaaccatcg	aggagagagt	aagagaaata	attatcaatg	1080
ctgttcggat	agaacaggag	ttcctcaactg	aggccttgc	tgtgaagctc	attgggatga	1140
attgcactct	aatgaagcaa	tacattgagt	ttgtggcaga	cagactttag	ctggaaactgg	1200
gttttagcaa	ggttttcaga	gttagagaacc	catttgactt	tatggagaat	atttcactgg	1260
aaggaaagac	taacttcttt	gagaagagag	taggcgagta	tcagaggatg	ggagtgtatgt	1320
caagtccaaac	agagaattct	tttaccccttgg	atgctgactt	ctaaatggac	tgaagatgtg	1380
cccttacttg	gctgattttt	tttttccatc	tcataagaaa	aatcagctga	agtgttacca	1440
actagccaca	ccatgaattt	tccgtaatgt	tcattaaacag	catctttaaa	actgtgttagc	1500
taccctcacaa	ccagtcctgt	ctgtttatag	tgctggtagt	atcacctttt	gccagaaggc	1560
ctggctggct	gtgacttacc	atagcagtga	caatggcagt	cttggcttta	aagtgagggg	1620
tgacccttta	gtgagcttag	cacagcggga	ttaaacagtc	ctttaaccag	cacagccagt	1680
taaaagatgc	agcctcactg	cttcaacgca	gattttatg	tttactttaaa	tataaacctg	1740
gcactttaca	aacaaataaa	cattgttttgc	tactcacggc	ggcgataata	gcttgattta	1800
tttggtttct	acaccaaata	catttcctg	accactaatg	ggagccaatt	cacaattcac	1860
taagtgacta	aagtaagttt	aacttgcgtt	gactaagcat	gtatatttttta	agtttttattt	1920
taatgaatta	aaatattttgt	taaccactt	taaagtcaat	cctgtgtata	cctagatattt	1980
agtcagttgg	tgccagatag	aagacaggtt	gtgtttttat	cctgtggctt	gtgttagtgc	2040
ctgggattct	ctgccccctc	tgatgttgcgt	gttgtgggat	aaaggaaatct	ctcaggggcaa	2100
ggagcttctt	aagttaaatc	actagaaattt	taggggtgtat	ctgggccttc	atatgtgtga	2160
gaagccgtt	catttttattt	ctcactgtat	tttccctcaac	gtctgggtga	tgagaaaaaaa	2220
ttcttgaaga	gttttcatat	gtgggagcta	aggtgtattt	gtaaaatttc	aagtcatcct	2280
taaacaat	gatccaccta	agatcttgc	cctgttaagt	ggtgaaatca	actagaggtg	2340
gttcctacaa	gttggttcatt	ctagttttgt	ttgggtgttgc	taggttgcgt	gagtttattt	2400
atttatattt	actatgtctg	ttaaatcaga	aattttttat	tatctatgtt	cttctagattt	2460
ttacctgttag	ttcataaaaaaa	aaaaaaaaaaa	aaaaaaaaaaa			2500